The U.S. Food and Drug Administration (FDA) has granted a “breakthrough therapy” designation to Moderna’s personalized mRNA skin cancer vaccine combined with a drug by Merck for treating patients with high-risk melanoma. The “breakthrough therapy” designation has been granted to Moderna’s mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Merck’s anti-PD-1 therapy KEYTRUDA…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`